


Anti-Human CD317 (BST2, PDCA-1) PE

Catalog Number: 12-3179

RUO: For Research Use Only. Not for use in diagnostic procedures.



Normal human peripheral blood cells were treated with human IFN alpha 2 and then stained with Anti-Human CD19 (HIB19) APC (cat. 17-0199) and Mouse IgG1, K Isotype Control PE (cat. 12-4714) (left) or Anti-Human CD317 (BST2, PDCA-1) PE (right). Cells in the lymphocyte gate were used for analysis.

Product Information

Contents: Anti-Human CD317 (BST2, PDCA-1) PE

Catalog Number: 12-3179

Clone: 26F8

Concentration: 5 μ L (0.25 μ g)/test

Host/Isotype: Mouse IgG1, kappa

Formulation: aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer

Temperature Limitation: Store at 2-8°C. Do not freeze. Light-sensitive material.

Batch Code: Refer to vial

Use By: Refer to vial

Contains sodium azide

Description

This 26F8 monoclonal antibody reacts with human CD317 (also known as BST2 and tetherin). CD317 is a 30-36-kDa type II transmembrane protein expressed on B cells and bone marrow stromal cells. Although reports have indicated that CD317 mRNA is detectable in activated T cells, protein expression in freshly isolated primary T cells and macrophages is undetectable. Moreover, certain T cell lines, such as Jurkat, do not express detectable levels of CD317 protein. However, CD317 expression can be induced in many cell types (e.g., T and B cells, 293T, and HeLa) by IFN α treatment. CD317 has been associated with pre-B cell growth and the terminal differentiation of plasma B cells. More recently, this molecule has been reported to prevent HIV-1 virion release from the surface of infected cells, leading to reuptake and degradation of the virus. This activity is inhibited by the HIV-1 accessory protein Vpu. CD317 has been identified as the ligand for the ILT7 receptor.

Applications Reported

This 26F8 antibody has been reported for use in flow cytometric analysis.

Applications Tested

This 26F8 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 μ L (0.25 μ g) per test. A test is defined as the amount (μ g) of antibody that will stain a cell sample in a final volume of 100 μ L. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

References

Miyagi E, Andrew AJ, Kao S, Strebel K. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. *Proc Natl Acad Sci U S A*. 2009 Feb 24;106(8):2868-73.

Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. *Cell Host Microbe*. 2008 Apr 17;3(4):245-52.

Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. *Nature*. 2008 Jan

Not for further distribution without written consent.

Copyright © 2000-2012 eBioscience, Inc.

Tel: 888.999.1371 or 858.642.2058 • Fax: 858.642.2046 • www.ebioscience.com • info@ebioscience.com

Anti-Human CD317 (BST2, PDCA-1) PE

Catalog Number: 12-3179

RUO: For Research Use Only. Not for use in diagnostic procedures.

24;451(7177):425-30.

Ishikawa J, Kaisho T, Tomizawa H, Lee BO, Kobune Y, Inazawa J, Oritani K, Itoh M, Ochi T, Ishihara K, et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. 1995 Genomics 26, 527–534.

Related Products

00-4222 Flow Cytometry Staining Buffer

12-4714 Mouse IgG1 K Isotype Control PE (P3.6.2.8.1)

17-0199 Anti-Human CD19 APC (HIB19)